Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research

Alcohol and Alcoholism

Volumn 35, Issue 6, 2000, Pages 537-547

  Kranzler, Henry R ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; CITALOPRAM; DISULFIRAM; FLUOXETINE; NALMEFENE; NALTREXONE; OPIATE ANTAGONIST; SEROTONIN AGONIST;

ADOLESCENT; AGED; ALCOHOLISM; CLINICAL TRIAL; COMORBIDITY; DRUG ABUSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; FEMALE; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; SUSTAINED RELEASE FORMULATION; TREATMENT INDICATION;

EID: 0033662326     PISSN: 07350414     EISSN: None     Source Type: Journal    
DOI: 10.1093/alcalc/35.6.537     Document Type: Review

References (83)

1. Techniques to enhance compliance with disulfiram
2. Reduction in alcohol intake in humans as a function of treatment with zimelidine: Implications for treatment
3. Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics
4. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a planycebocontrolled trial
5. Alcoholism treatment by disulfiram and community reinforcement therapy
6. Effect of citalopram on alcohol intake in heavy drinkers
7. Is disulfiram implantation effective?
8. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study
9. How effective is the standard dose of disulfiram? A review of the alcohol-disulfiram reaction in practice
10. Manual-guided psychosocial treatment: A new virtual requirement for pharmacotherapy trials?
11. Disulfiram treatment of alcoholism
12. United Kingdom multicentre acamprosate study (UKMAS): A six-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol
13. Carbon disulfide and N,N-diethyldithiocarbamate generate thiourea cross-links on erythrocyte spectrin in vivo
14. Disulfiram treatment of alcoholism: A Veteran's Administration Cooperative Study
15. Pharmacological treatment of alcohol dependence: A review of the evidence
16. Acamprosate and prevention of relapse in alcoholics
17. Effects of fluoxetine and Ca-acetylhomotaurinate on alcohol intake in familial and nonfamilial alcohol patients
18. Overview of pharmacologic treatment approaches for alcohol and other drug addiction. Intoxication, withdrawal, and relapse prevention
19. Effect of fluoxetine on alcohol consumption in male alcoholics
20. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolyase in normal and disease states using immunochemical analysis of surgical liver samples
21. A drug sensitizing the organism to ethyl alcohol
22. In vitro and in vivo inhibition of rat liver aldehyde dehydrogenase by S-methyl N,N-diethylthiolcarbamate sulfoxide: A new metabolite of disulfiram
23. Naltrexone treatment of comorbid alcohol and cocaine use disorders
24. Naltrexone, relapse prevention and supportive therapy with alcoholics: An analysis of patient treatment matching
25. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics
26. Ondansetron reduces the drinking of biologically predisposed alcoholics
27. A double blind study of fluoxetine in severe alcohol dependence: Adjunctive therapy during and after inpatient treatment
28. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey
29. Use and misuse of the concept of craving by alcohol, tobacco, and drug researchers
30. The pharmacology of alcohol abuse: An introduction
31. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism
32. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders
33. Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism
34. Placebocontrolled trial of fluoxetine as an adjunct to relapse prevention in alcoholics
35. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in Type B alcoholics
36. Methodological issues in pharmacotherapy trials with alcoholics
37. Sustained-release naltrexone for alcoholism treatment: A preliminary study
38. Placebocontrolled trial of naltrexone vs. nefazodone for treatment of alcohol dependence
39. Subtypes of alcoholism and their role in therapy
40. Ability of calcium bis acetyl homotaurinate, a GABA agonist, to prevent relapse in weaned alcoholics
41. Acamprosate appears to decrease alcohol intake in weaned alcoholics
42. Acamprosate in alcohol dependence: How does it work?
43. The neurobiology of craving: Potential mechanisms for acamprosate
44. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETCMe): The terminal step in the bioactivation of disulfiram
45. Methodological and behavioral therapy of the US acamprosate study
46. Acamprosate for the treatment of alcohol dependence: A review of double-blind, placebo-controlled trials
47. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence
48. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence
49. The effects of psychosocial services in substance abuse treatment
50. Closing the gap between alcoholism research and practice: The case for pharmacotherapy
51. New drag treatments for alcohol problems: A critical appraisal
52. The quality of alcohol treatment research: An examination of influential controlled trials and development of a quality rating system
53. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers
54. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers
55. The serotonin uptake inhibitor citalopram attenuates ethanol intake
56. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers
57. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence, and problems
58. Differential effects of viqualine on alcohol intake and other consummatory behaviors
59. Naltrexone and coping skills therapy for alcohol dependence: A controlled study
60. Experience of a 'slip' among alcoholics treated with naltrexone or placebo
61. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence
62. Naltrexone as an adjunctive treatment for older patients with alcohol dependence
63. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol
64. Acamprosate in the treatment of alcohol dependence: A 6-month postdetoxification study
65. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study
66. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype
67. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme
68. The 'file drawer problem' and tolerance for null results
69. Does acamprosate diminish the appetite for alcohol in weaned alcoholics?
70. Relapse prevention by acamprosate: Results from a placebo controlled study on alcohol dependence
71. New treatment options for substance abuse from a public health viewpoint
72. Naltrexone-induced alterations in human ethanol intoxication
73. Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study
74. Citalopram in the treatment of alcoholism: A double-blind placebo-controlled study
75. Naltrexone in the treatment of alcohol dependence
76. Effect of naltrexone on alcohol 'high' in alcoholics
77. Naltrexone and alcohol dependence: Role of subject compliance
78. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence
79. Alcoholic liver disease limits disulfiram-alcohol reaction. Alcoholism:
80. Disulfiram implantation: A trial using placebo implants and two types of controls
81. Diethyldithiocarbamic acidmethyl ester: A metabolite of disulfiram and its alcohol sensitizing properties in the disulfiram-ethanol reaction
82. Disulfiram metabolism as a requirement for the inhibition of rat liver mitochondrial low Km aldehyde dehydrogenase